EPRX Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Eupraxia Pharmaceuticals (TSE: EPRX)
›
Eupraxia Pharmaceuticals (TSE: EPRX) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.
The shares were at 8.780 CAD on 19 November 2026, up 10.3% over 52 weeks. Its 52-week range is 7.350 CAD to 13.08 CAD: the price is 32.9% below the high and 19.5% above the low.
Its market capitalisation is 590.62M CAD.
Eupraxia Pharmaceuticals reports return on equity of -47.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 123.00M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 17.65 CAD is 101.0% above the current price. The next earnings report is expected on 16 March 2027.